Bulumtatug fuvedotin not checked

Mabwell · 9MW2821

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
11 active
13 in total
Targets
 

What this is

How it works
An antibody: a lab-made immune protein built to latch onto one target in the body.-tug: unmodified immunoglobulins WHO name stem
How it’s given
“1.25mg/kg of 9MW2821 by intravenous infusion on days 1, 8 and 15 of every 28-day cycle”In the company’s words, NCT06196736 on ClinicalTrials.gov
Tested for
Urothelial Carcinoma (3 trials), Advanced Urothelial Carcinoma (2 trials), Cervical Cancer, Locally Advanced or Metastatic Triple-negative Breast Cancer, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent, Urothelial Carcinoma of the Renal Pelvis and Ureter, Triple-Negative Breast Cancer and 3 more
Main trialPhase 3
“The purpose of this study was to compare the antitumor activity of 9MW2821 and chemotherapy in participants with locally advanced or metastatic urothelial cancer previously treated with PD-(L)1 inhibitor and platinum-containing chemotherapy.”In the company’s words, NCT06196736 on ClinicalTrials.gov
Other names
9MW2821

Other drugs for Urothelial Carcinoma

All 83 drugs for Urothelial Carcinoma

Coming up7

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials13

TrialPhaseCompletesWhat it tests
Phase 3Recruiting Sep 2026 A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer
Phase 3Recruiting Sep 2027 9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer
Phase 3Recruiting 9 Dec 2027 A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer
Phase 3Not yet recruiting Dec 2027 A Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast Cancer
Phase 2Recruiting Jun 2026 9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma
Phase 2Recruiting Jul 2026 A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer
Phase 2Recruiting 31 Dec 2027 9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer
Phase 1/2Not yet recruiting Apr 2026 A Clinical Study of 9MW2821 Monotherapy or Combined With Other Anticancer Therapy in Advanced Solid Tumors
Phase 1/2Recruiting 31 Dec 2026 9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer
Phase 1/2Not yet recruiting 1 May 2027 9MW2821 Combined With Other Antitumor Drugs in Patients With Advanced Gynecological Tumors
Phase 1Recruiting May 2027 A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
Phase 1/2Unknown Dec 2025 A Clinical Study of 9MW2821 in Subjects With Advanced Malignant Solid Tumors
Phase 1Unknown 31 Dec 2024 A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Bulumtatug fuvedotin

Following is part of Solo: you see every change to Bulumtatug fuvedotin the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in